posted on 2021-06-15, 03:25authored byChristof C. Smith, Kelly S. Olsen, Kaylee M. Gentry, Maria Sambade, Wolfgang Beck, Jason Garness, Sarah Entwistle, Caryn Willis, Steven Vensko, Allison Woods, Misha Fini, Brandon Carpenter, Eric Routh, Julia Kodysh, Timothy O’Donnell, Carsten Haber, Kirsten Heiss, Volker Stadler, Erik Garrison, Adam M. Sandor, Jenny P. Y. Ting, Jared Weiss, Krzysztof Krajewski, Oliver C. Grant, Robert J. Woods, Mark Heise, Benjamin G. Vincent, Alex Rubinsteyn
Additional file 2: Table S1. All SARS-CoV-2 MHC-I ligands contained in the top 5% of U.S. HLA alleles. Table S2. All SARS-CoV-2 MHC-II ligands contained in the top 5% of U.S. HLA alleles. Table S3. All SARS-CoV-2 MHC-I ligands contained in the top 5% of worldwide HLA alleles. Table S4. All SARS-CoV-2 MHC-II ligands contained in the top 5% of worldwide HLA alleles. Table S5. Summary of SARS-CoV-1 MHC ligands previously described in the literature. Table S6. SARS-CoV-2 B cell linear epitopes from array/mapping studies. Table S7. SARS-CoV-2 T cell epitopes within S, M, and N proteins. Table S8. SARS-CoV-2 T cell epitopes within all proteins. Table S9. Curated a dataset of published T cell epitope mapping studies.
Funding
Susan G. Komen National Cancer Institute V Foundation for Cancer Research